Form 4: Champions Oncology Director Acquires Options in Company Stock

Joel Ackerman, a director at Champions Oncology, acquired options to purchase 43,190 shares of common stock.

Summary

• Joel Ackerman, a director of Champions Oncology, Inc., has reported the acquisition of options to purchase 43,190 shares of the company's common stock.
• The options were granted on November 12, 2024, at an exercise price of $4.64 per share.
• These options vest over a twelve-month period, with vesting dates on November 12, 2024, February 12, 2025, May 12, 2025, and August 12, 2025.
• The options expire on November 12, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant to a director. It is neither particularly positive nor negative, but indicates a standard practice of executive compensation.

Positives

• The acquisition of options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who acquire or dispose of company securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The vesting schedule of the options is typical for executive compensation packages.

Stakeholder Impact

• The acquisition of options by a director may be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Champions Oncology, stock options, director, Joel Ackerman, equity, insider trading, Form 4